Jefferies Boosts Price Target, Estimates on Pfizer (PFE)
Due to an expected big year for clinical drug results, Jefferies analysts increased the price target and earning estimates on pharmaceutical company Pfizer Inc. (PFE).
The analysts maintain a “Buy” rating for PFE and now see shares reaching $31, suggesting a +16.4% upside to Tuesday’s closing price of $26.62.
Pfizer shares were down slightly during premarket trading on Wednesday. The stock is up +21.89% over the past year.
The Bottom Line
We have been recommending shares of Pfizer (PFE) since Mar.2, 2012, when the stock was trading at $21.49. The company has a 3.61% dividend yield, based on last night’s closing stock price of $26.62.
Pfizer Inc. (PFE) is recommended at this time, holding a Dividend.com DARS™ Rating of 3.5 out of 5 stars.
Get FREE Dividend Tips, Updates & MoreWe respect your privacy
- Powerful dividend insights sent every weekday morning
- Gain instant access to actionable investing tips
- Strategically grow your portfolio’s profitability